Barclays PLC raised its holdings in Accolade, Inc. (NASDAQ:ACCD - Free Report) by 164.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 139,901 shares of the company's stock after acquiring an additional 86,981 shares during the quarter. Barclays PLC owned about 0.17% of Accolade worth $539,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Mission Creek Capital Partners Inc. acquired a new stake in shares of Accolade in the 3rd quarter valued at $38,000. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in Accolade during the third quarter valued at about $46,000. Wolverine Trading LLC acquired a new stake in shares of Accolade in the third quarter worth about $51,000. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Accolade by 1,144.1% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company's stock worth $81,000 after acquiring an additional 19,232 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Accolade during the 3rd quarter valued at about $96,000. 84.99% of the stock is owned by institutional investors.
Accolade Price Performance
Shares of ACCD stock traded up $0.03 during mid-day trading on Friday, reaching $6.89. The company's stock had a trading volume of 2,414,827 shares, compared to its average volume of 2,006,093. The firm's 50-day moving average is $4.08 and its two-hundred day moving average is $3.90. The company has a market cap of $554.92 million, a P/E ratio of -3.06 and a beta of 2.08. Accolade, Inc. has a 1-year low of $3.08 and a 1-year high of $13.93. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.72 and a current ratio of 2.72.
Accolade (NASDAQ:ACCD - Get Free Report) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.01. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%. On average, research analysts predict that Accolade, Inc. will post -0.92 earnings per share for the current year.
Analysts Set New Price Targets
ACCD has been the subject of several analyst reports. Morgan Stanley reduced their target price on Accolade from $6.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Canaccord Genuity Group restated a "hold" rating on shares of Accolade in a report on Wednesday, January 8th. Wells Fargo & Company dropped their price objective on Accolade from $7.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Friday, October 11th. Raymond James reaffirmed a "market perform" rating on shares of Accolade in a research report on Thursday, January 9th. Finally, Stifel Nicolaus reissued a "hold" rating and issued a $7.03 price target (down from $8.00) on shares of Accolade in a report on Thursday, January 9th. Twelve equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Accolade presently has an average rating of "Hold" and a consensus price target of $7.55.
Check Out Our Latest Stock Analysis on ACCD
Insider Activity
In other news, CEO Rajeev Singh sold 13,357 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total value of $48,085.20. Following the transaction, the chief executive officer now directly owns 814,316 shares of the company's stock, valued at $2,931,537.60. The trade was a 1.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 41,298 shares of company stock worth $149,987. Corporate insiders own 8.20% of the company's stock.
Accolade Company Profile
(
Free Report)
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.
Read More
Before you consider Accolade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accolade wasn't on the list.
While Accolade currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
